PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) are a group of antibodies designed to block specific targets present on tumor cells or lymphocyte surfaces (e.g., ipilimumab [20], the first approved anti-CTL4 antibody, and nivolumab [21,22,23,24] first approved anti-PD-1 antibody), consequently boosting the immune system to attack cancer.